Member Info for Canis

Whilst negotiating the subscription deal I'm assuming Lanstead had access to information we PI's aren't privy to - why else would they invest 2.66 million?
The amount of monies payable to immupharma through the subscription is dependent on the share price being higher or lower than a base price of 13.33p. The payments are due to commence in a couple of months, therefore I'm expecting positive news flow from Immupharma over the next few weeks in order to maintain and improve share price otherwise the subscription payments will be lower than anticipated.

Just hope there is no world record! lol

Firstly, let's see proven efficacy through the extension study results, Immupharma would then have a stronger hand. They are currently engaged with potential partners, therefore you could assume they have already had some positive feedback from the extension study. Up to ten weeks from now will perhaps answer a lot of questions!

For me watching and reading about this share for a year or so I'm thinking that the urgency needs to be getting a deal done with a partner, and that means one with deep pockets - not with the likes of Incanthera who are just as cash strapped as Immupharma. By the company's own admission they will have to conduct another Phase III study for which there isn't enough money in the pot! The extension trial nor MAP will be enough to gain approval with FDA, however some positive findings will boost SP which could help with a further cash raising. I'm holding for now!